CIC
NGM

Cornercap Investment Counsel’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Cornercap Investment Counsel’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-51,176
Closed -$54.8K – 665
2023
Q3 		$54.8K Sell
51,176
-545
-1% -$1.13K 0.01% 542
2023
Q2 		$134K Buy
51,721
+5,659
+12% +$20.2K 0.02% 539
2023
Q1 		$188K Hold
46,062
– – 0.03% 508
2022
Q4 		$231K Buy
46,062
+34,563
+301% +$217K 0.04% 501
2022
Q3 		$150K Hold
11,499
– – 0.03% 515
2022
Q2 		$147K Buy
+11,499
New +$159K 0.03% 507

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornercap Investment Counsel's NGM Position: Q4 2023 in Review

Cornercap Investment Counsel sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 51,176 shares — an estimated $54.8K sold.

Cornercap Investment Counsel first reported a position in NGM in Q2 2022 and held it in 6 quarters. The position peaked at $231K in Q4 2022. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Cornercap Investment Counsel reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 51,176 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $54.8K.
  • Cornercap Investment Counsel first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Cornercap Investment Counsel's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $231K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Cornercap Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.